What NewAmsterdam Pharma Company N.V.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 1 |
| Sells | 3 | 43 |
| Total trades | 7 | 81 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 81 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Sep 30 | Open-market sale · S | −50,246 | $25.03 | −$1.26M | 69,302 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Sep 30 | Exercise / conversion · M | +50,246 | — | — | 119,548 |
| Davidson Michael H. | Chief Executive Officer | Sep 14 | Open-market buy · P | +10,000 | $22.65 | +$227K | 792,923 |
| Smither John W | Director | Sep 04 | Open-market sale · S | −1,600 | $25.32 | −$40.5K | 8,760 |
| Gunning Robert William | Vice President, Controller | Sep 01 | Grant / award · A | +3,200 | — | — | 3,200 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Aug 24 | Open-market sale · S | −125,000 | $26.91 | −$3.36M | 69,302 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Aug 24 | Exercise / conversion · M | +125,000 | — | — | 194,302 |
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 | Open-market sale · S | −2,915 | $31.71 | −$92.4K | 24,353 |
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 | Open-market sale · S | −31,885 | $31.05 | −$990K | 27,268 |
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 | Open-market sale · S | −70,200 | $29.96 | −$2.1M | 59,153 |
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 | Exercise / conversion · M | +80,000 | $11.17 | +$894K | 129,353 |
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 | Exercise / conversion · M | +25,000 | $11.90 | +$298K | 49,353 |
| Kooij Louise Frederika | Chief Accounting Officer | Jun 22 | Open-market sale · S | −300 | $30.73 | −$9.22K | 24,353 |
| Kooij Louise Frederika | Chief Accounting Officer | Jun 22 | Open-market sale · S | −39,700 | $30.20 | −$1.2M | 24,653 |
| Kooij Louise Frederika | Chief Accounting Officer | Jun 22 | Exercise / conversion · M | +15,000 | $11.90 | +$179K | 64,353 |
| Kooij Louise Frederika | Chief Accounting Officer | Jun 22 | Exercise / conversion · M | +25,000 | $10.90 | +$273K | 49,353 |
| Kooij Louise Frederika | Chief Accounting Officer | May 26 | Open-market sale · S | −65,000 | $35.69 | −$2.32M | 24,353 |
| Kooij Louise Frederika | Chief Accounting Officer | May 26 | Exercise / conversion · M | +5,000 | $10.90 | +$54.5K | 89,353 |
| Kooij Louise Frederika | Chief Accounting Officer | May 26 | Exercise / conversion · M | +60,000 | $10.00 | +$600K | 84,353 |
| Lange Louis G | Director | Mar 11 | Open-market sale · S | −446 | $31.23 | −$13.9K | 10,360 |
Loading...
